Introduction
Accumulating evidence has shown that inflammation might be involved in the pathophysiology and treatment response of depression (Syed et al. 2018) . Patients with depression show enhanced serum levels of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor alpha (TNF-α) (Al-Hakeim et al. 2015) . In contrast, anti-depressant medication can decrease the concentration of pro-inflammatory cytokines (Hashimoto et al. 2015; Gupta et al. 2016) . This phenomenon has also been shown in depression-like animal models (Ge et al. 2015) . For example, lipopolysaccharide (LPS) treatment leads to depressive behaviors accompanied by an increased production of pro-inflammatory cytokines in mice (O'Connor et al. 2009a ). Recent studies have indicated that glutamate excitotoxicity participates in cellular damage from repeated LPS infusion in the central nervous system (CNS) (Tanaka et al. 2006; , and the use of antagonists of N-methyl-D-aspartate receptor (a glutamate receptor subtype) has been shown to be effective in alleviating depression (Willard et al. 2000; Walker et al. 2013a ). Thus, both inflammation and alterations in glutamate neurotransmission are suggested to be involved in the pathophysiology of depression .
Astroglial glutamate transporters are responsible for glutamate uptake, which plays a key role in regulating glutamate transmission and maintaining extracellular glutamate concentrations below neurotoxic levels (Frizzo et al. 2001 ). However, the activation of astrocytes leads to impaired glutamate clearance and oxidative stress, which contribute to excitotoxicity (Tilleux et al. 2007a) . Proinflammatory mediators released from activated microglial cells can downregulate glutamate transporters in astrocytes (Zhao et al. 2004; Tilleux et al. 2007b) . For example, inflammatory molecules, such as IL-1β and TNF-α, that are released during immune activation suppress astrocytic expression of GLT-1 and GLAST glutamate transporters (similar to EAAT2 and EAAT1 in humans) (Korn et al. 2005; Wang et al. 2013) .
MicroRNAs (miRNAs) are a class of small noncoding RNAs that negatively regulate gene expression at the posttranscriptional level, predominantly through complimentary binding to the 3` untranslated regions (UTRs) of target genes (Lai 2002) . Seventy percent of miRNAs are expressed in the brain (Babak et al. 2004) , and several miRNAs have been shown to mediate the function of astrocytes in the CNS Pogue et al. 2010; Gomes et al. 2018 ). Among these miRNAs, miR-32-5p has been extensively studied and is considered to be a promising target for cancer, obesity, and metabolic syndrome therapies (Munthe et al. 2017; Zhao et al. 2017 ). Our previous study showed that microRNA-32-5p promoted calcification in vascular smooth muscle cells and was positively associated with coronary artery calcification . Calcification is a pathological condition associated with several diseases found to be closely associated with depression (Lin et al. 2018a) , and whether microRNA-32-5p contributes to depression is of interest. A recent study indicated that miR-32-5p induced pro-inflammatory cytokine production in LPS-treated spinal glia cells and contributed to neuropathic pain (Yan et al. 2018) in the CNS, which implied that miR-32-5p might be a modulator of glial function.
In the present study, utilizing a miR-32-5p knockout mouse model, we found that miR-32-5p knockout eliminated LPS-induced depression-like behavior by regulating astrocytic and glutamatergic signaling in the hippocampus and prefrontal cortex.
Materials and methods

Animals
Twelve-to sixteen-week-old adult male C57BL/6 mice that weighed 25-30 g (obtained from the Hunan SJA Lab Animal Center of Changsha, Hunan, China) and miR-32-5p knockout (KO) littermates (obtained from Shanghai Model Organisms of Shanghai, China) were used in this study. The miR-32-5p KO mice were generated on a C57BL/6 background using CRISPR/CAS9 technology, and the miR-32-5p base sequence was GTTGCATGTTGTCACGGCCTCAATGCAATT for the WT mice and GTTGCATTGAGGCCTCAATGCAATT for the KO mice. Mice were group-housed (2-5 mice per cage) at a controlled temperature (22 ± 2°C) under a 12-h light/dark cycle with free access to food and water. The mice adapted to their new environment for 7 days before the behavioral tests. All animals were used for only one procedure.
The experimental protocol was approved by the Animal Care and Use Committee of the University of South China and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Drugs
LPS from Escherichia coli 026: B8 (Sigma, USA) was dissolved in 0.9% NaCl.
Based on a previous study (O'Connor et al. 2009b ), both KO and WT mice were treated with a single i.p. injection of LPS (0.83 mg/kg) to establish the animal model of depression, and an equal volume of saline was administered to another cohort of mice as a vehicle control group. The sucrose preference test (SPT) was performed 0-20 h after LPS injection, the open field test (OFT) and forced swimming test (FST) were performed 21-23 hr after LPS treatment, and the tissues were collected from experimental animals 24 hr after LPS injection. The experimental timeline is shown in 
Open field test
The open field test was performed to assess anxiety-like behavior as described in a previous study (Xu et al. 2015) . Briefly, the mice were placed in the quiet experiment room for at least 1 hr prior to the behavioral test. The open field apparatus was 40 cm × 40 cm × 25 cm (length × width × height), and the bottom of the field was equally divided into 25 squares. Each mouse was placed directly in the center of the open field and allowed to freely explore the arena for 5 min. When finished, the animal was returned to its home cage. The apparatus was then cleaned with 70% ethanol and air-dried for an additional 5 min. The animal behaviors were recorded using a video camera. An observer who was blinded to the experimental condition coded the videotapes. A greater amount of time spent in the center of the 9 squares indicates a lower anxiety level. The total number of squares crossed during the testing session represented the locomotor activity.
Elevated plus-maze test
The elevated plus-maze test was also used to evaluate anxiety-like behavior as described in a previous study (Xu et al. 2015) . Briefly, after habituation for 1 hr in the quiet experiment room, each animal was placed in the middle of the elevated plus-maze apparatus, which included two open arms and two closed arms 50 centimeters from the ground. The free movements of the mice were recorded by a video camera over the 5-minute testing session. The maze was cleaned after each trial with 70% ethanol and air-dried for an additional 5 min. An observer who was blinded to the experimental condition coded the videotapes. The percentage of time spent in the open arms was an index of anxiety-like behavior.
Sucrose preference test
The sucrose preference test was modified to detect depression-like behavior according to a previous study (Xu et al. 2015) . Briefly, the mice were individually housed in a standard cage for 3 days with a 100 ml bottle of 1% (w/v) sucrose solution. On the fourth day, the mice were given a free choice between 1% sucrose solution and tap water for 20 hr. The position of the two bottles was switched every 10 hr to avoid a side preference. The consumption of water and sucrose solution was estimated by weighing the bottles before and after the test by an observer who was blinded to the experimental condition. The sucrose preference was calculated as follows: preference % = [(sucrose consumption/ (sucrose + water consumption)) ×100%].
Forced swimming test
The forced swimming test was used to assess depression-like behavior as described in a previous study (Xu et al. 2015) . Briefly, the mice were individually placed in an open cylinder (25 cm×10 cm, height × diameter), which contained water 10 cm high at 23°C. Each animal was forced to swim for 6 min, and the immobility time was calculated during the last 4 min by an observer who coded the videotapes and was blinded to the experimental condition. After each trial, the water in the containers was changed.
Novel object recognition test
The novel object recognition test was carried out as described in a previous study (Xu et al. 2015) . The test was divided into a training period and an experimental test.
During training, two randomly selected objects of the same shape were presented to each mouse for 5 min. One hour after training, another set of objects (one previously presented object and one novel object) was presented to the trained mice. The interactions of each mouse with each object were scored when an animal sniffed or touched the object or moved toward the object in such a way that the distance between the tip of the nose and the object was less than 1 cm. The animal should prefer the novel object if it retained the memory of the previously encountered object.
The preference for exploring a novel object was measured by estimating individual discrimination ratios (the difference between the number of approaches exploring the novel and the familiar objects divided by the total number of approaches exploring both objects).
Social interaction test and social recognition test
The social interaction and social recognition tests were conducted in the open field chamber over 10 min. This experiment was divided into two phases. In the first 5 min, a cylindrical cage with the mice being tested was placed in the center of the six grids on one side of the open field, and the time that the experimental mice spent in the six-square area over 5 min was recorded (social interaction test). After 5-10 min, another mouse was placed in the other side in a symmetric position (new), and the time spent in the six-square area over 5 min was individually measured for each mouse (social recognition test). The test mice had a choice between the previously investigated mouse (familiar) and a novel unfamiliar mouse (novel). The discrimination ratio was calculated using the following formula: [(time sniffing the new cage-time sniffing the familiar cage)/total sniffing time spent on the two cages].
Nissl stain
After the behavioral tests, the mice were anesthetized with an overdose of 10% sodium pentobarbital (80 mg/kg) and transcardially perfused with saline and 4% paraformaldehyde. The brains were removed and fixed in 4% paraformaldehyde for 24 hr and then cryoprotected with 30% phosphate-buffered sucrose overnight.
Coronal sections (30 µm) of the brain were obtained using a cryostat at -20°C for further staining. Nissl staining was performed as previously described (Xu et al. 2015) .
Free-floating sections were washed with 0.01 M PBS 3 times. Then, we mounted the sections onto gelatin-coated slides. When the sections dried, 0.5% cresyl violet (Sigma, USA) was added. After thirty minutes, the cresyl violet solution was removed.
The sections were then dehydrated through graded alcohol (70%, 80%, 90% and 100%×2), placed in xylene, and covered with a cover-slip. Images were subsequently captured using a Nikon light microscope (Ming Mei, China).
Immunofluorescence in situ hybridization
Free-floating sections were washed with 0.01 M PBS 3 times, for 10 min each time. Then, the sections were treated with 3% pepsin (Boster, China) for 120 s at room temperature. After prehybridization at 40°C for 2 hr, the sections were incubated with a probe specific to miR-32-5p at 40°C overnight in hybridization buffer, followed by washing the sections with 2 X SSC, 0.5 X SSC and 0.2 X SSC.
The sections were then incubated with mouse-anti-digoxigenin-biotin for 60 min at 37°C and SABC-cy3 regent for an additional 60 min at 37°C. The sections were subsequently washed with 0.02 M PBS. All images were captured and obtained in the same conditions by using a ZEISS fluorescence microscope (ZEISS, Germany).
Immunohistochemistry
Free-floating sections were washed with 0.01 M PBS 3 times, for 10 min each time. The sections were treated with 3% H 2 O 2 for 20 min to remove endogenous peroxidase, which was then blocked by placing the slices in 5% sheep serum that contained 0.1% Triton X-100 for 2 hr at room temperature. The sections were subsequently incubated in 5% BSA in 0.1 M PBS for 2 hr, followed by immunostaining with the rabbit anti-NeuN primary antibody (1:1000, CST) or rabbit anti-GFAP primary antibody (1:1000, Boster) for 2 hr at room temperature prior to incubation at 4°C overnight. The sections were then incubated in secondary reagents that included biotinylated rabbit anti-goat immunoglobulin (CWBIO) for 2 hr.
Diaminobenzidine tetrahydrochloride (DAB) (ZSGB-BIO) was used as a peroxidase substrate. Washing for all procedures with the exception of the blocking step was performed using 0.01 M PBS. All sections were mounted onto gelatin-coated slides, dehydrated in a graded ethanol series and xylene and then cover-slipped. All images were captured and obtained in the same conditions by using a Nikon light microscope (Ming Mei, China). Immuno-positive NeuN cells were counted in six sections from each animal by a researcher who was blinded to the treatment used.
Western blot
Mice were anesthetized with an overdose of 10% sodium pentobarbital (80 mg/kg), and the samples were rapidly removed following decapitation. The samples were homogenized in a lysis buffer that contained phenylmethysulforyl fluoride (PMSF) (CWBIO). The samples were then centrifuged, and the protein concentration was measured using a BCA Assay Kit (CWBIO). The sample extracts were then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 100 V for 1.5 hr and transferred onto nitrocellulose membranes for 2 hr at 90 V.
Then, the membranes were blocked with 5% nonfat milk for 2 hr at room temperature and incubated with the primary antibodies rabbit anti-NeuN (CST), rabbit anti-GFAP (Boster), rabbit anti-GluR1 (Boster), rabbit anti-GluR2 (Boster), rabbit anti-NMDAR1 (Abclonal), rabbit anti-NMDAR2A (Boster), rabbit anti-NMDAR2B (Proteintech), rabbit anti-VGLUT2 (Proteintech), rabbit anti-EAAT1 (Proteintech) or mouse anti-tubulin (Proteintech) overnight in 5% skim milk solution at 4°C. The next day, after washing three times in 0.02 M Tween-Tris buffered solution, the membranes were incubated with horseradish peroxidase (HRP)-conjugated donkey anti-rabbit or donkey anti-goat polyclonal secondary antibodies (1:1000, CWBIO) for 2 hr at room temperature. The signals were detected by an enhanced chemiluminescence (ECL) system (CWBIO). The protein levels were quantified by densitometry using NIH ImageJ (NIH, Bethesda, MD, USA).
RNA Isolation and Real Time-PCR
Mice were decapitated, the brains were removed and the hippocampus and prefrontal cortex were isolated and frozen at −80°C. miRNA was extracted with miRNA Purification Kits (CWBIO), and total RNA was extracted by Trizol ® reagent (CWBIO) according to the manufacturer's instructions. The RNA purity was determined by the A260 nm/A280 nm absorption ratio. cDNA synthesis from miRNA was performed with the Mir-X TM miRNA First Strand Synthesis Kit (Takara), and total RNA cDNA synthesis was performed with the RevertAid TM First Strand cDNA Synthesis Kit (Fermentas) according to the manufacturer's instructions using 0.25 μg of miRNA and 2 μg of total RNA. The cDNA was stored at -20°C. Gene expression was determined by an ABI-7500 real-time PCR system with TB Green TM Premix Ex Taq TM II (Takara). U6 or GAPDH gene expression was used as the internal control.
The primers for U6 and miRNA-32-5p were purchased from TianGen. Other primers were designed with Primer 3 software. A two-step PCR protocol was used according to the manufacturer's instructions. The PCR cycling conditions were 30 s at 95°C followed by 40 cycles at 95°C for 10 Genes Primers GAPDH GAPDH forward reverse forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse  forward  reverse   GGACTGCAAAACATAGCTGTAG  GACTTGCTATTTCTGAGCCATG  CAACCAACAAGTGATATTCTCCATG  GATCCACACTCTCCAGCTGCA  GTTCCTGACTTGTTTGAAGACC  GTTGGACATCTTTGACGTTTCA  GTGCCTATGTCTCAGCCTCT  TGGTTTGTGAGTGTGAGGGT  GCTATGGCCGCTTTGATGTG  TCGAACTCCAATCTCGGTGC  TTTTTGTCACCAAGCTCAAGAG  TTCTGATCTCATTTGGTTCCGA  CAACTGCATCCATATCGATGAC  GATTCCGGATTCAGACATCTCT  TCCTGGAACAGCAAAACAAG  CAGCCTCAGGTTGGTTTCAT  GCAGCAGTGGAGGACAAGTGAC  CCGCCATCACCTTCACACCATC  AACAAATGGTGGTACGACAAAG  TGTAGAATACTCCAGCAACGTT  TCTTGGAAGATACAGCTCAACG  GAGTAGATGGACATTCGGGTAG  GAACGCGAACTTCGAAATCTG  GTCAGTGCGGTTCATCAATAAC  AAGAAGAATCGGAACAAACTGC  CAGCTGGCATCTCAAACATATG  GCTGCGATACTGCTCACCTCTAC  AGCCAACCTACTCCTCTCCAAGG  CAGAGAAGGTAAAATCGTGCAG  TTTAAAGCAGGCTTCTACCAGA s and 60°C for 30 s. The samples were processed in technical duplicates, and a melting analysis was performed for each sample at the end of PCR. The 2 -△△Ct method was used to determine the relative gene expression as described in our previous study (Cao et al. 2014 ).
Statistical analyses
All statistical analyses were conducted with GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). Data are presented as the mean±SEM.
Significant differences were determined using Student's t-tests for two-group comparisons or ANOVAs followed by Bonferroni's post hoc testing for multiple comparisons among more than two groups. P<0.05 was considered statistically significant.
Results
MiR-32-5p was widely expressed in prefrontal cortex and hippocampus in WT mice
To determine whether miR-32-5p was expressed in the prefrontal cortex and hippocampus in WT mice, we performed immunofluorescence in situ hybridization.
The results showed that miR-32-5p was widely expressed in the PFC and the CA1, CA2, CA3 and DG of the hippocampus (HIP) ( Fig. 1 ).
MiR-32-5p knockout did not lead to neuronal loss in the mouse brain
To determine whether miR-32-5p knockout leads to potential toxicity in neurons, we performed both Nissl staining and NeuN immunohistochemistry ( Fig. 2A ). With
Nissl staining, we did not identify aberrant morphology in either the hippocampus or suggested that miR-32-5p knockout did not cause neuronal toxicity.
MiR-32-5p knockout did not affect general behavior in mice
To explore the effect of miR-32-5p knockout on animal behavior, several behavioral tests, including anxiety-like, depression-like and social behavioral tests, were performed in mice. In the elevated plus-maze test, no difference was identified in the time spent in the open arms between the WT and KO mice (t = 1.629, P = 0.1105) (Fig. 3A ). There were no differences in the time spent in the inner area (t = 0.4386, P = 0.6624) ( Fig. 3B ) or in locomotor activity (t = 1.577, P = 0.1195) ( Fig.   3C ) between the WT and KO mice in the open field test. Depression-like behavior was assessed in mice using the forced swimming test (FST) and sucrose preference test (SPT). Although the KO mice showed a reduced immobility time compared to the WT mice in the FST, this difference did not reach statistical significance (t = 1.570, P = 0.1328) ( Fig. 3D ). We found that the KO mice did not show a significantly altered preference for sucrose compared to the WT mice in the SPT (t = 1.664, P = 0.1030) ( Fig. 3E ). These results indicated that miR-32-5p knockout had no obvious effect on animal anxiety or depression-like behaviors. The novel object recognition test and social recognition test were then performed to examine the social behaviors in mice.
In the novel object recognition test, no difference was observed in the discrimination ratio between the WT and KO mice (t = 0.6451, P = 0.5231) ( Fig. 3F ). In addition, the KO mice showed normal social cognition as no differences were identified in the time spent on the novel social target side between the WT and KO mice (t = 1.078, P = 0.2971) (Fig. 3G ), and no difference was observed in the time spent in the social target area between the WT and KO mice (t = 0.7588, P = 0.4626) ( Fig. 3H ) in the social recognition test. Taken together, these behavioral test results indicated that miR-32-5p knockout had no effect on the anxiety-like, depression-like or social behaviors of mice.
LPS treatment induced enhanced expression of miR-32-5p in the animals' prefrontal cortex and hippocampus
To further explore the role of miR-32-5p in pathological conditions, we exposed male C57BL/6 mice to LPS and measured the expression of miR-32-5p. We found that LPS exposure significantly increased the expression of miR-32-5p in the hippocampus (t = 2.419, P = 0.0419) ( Fig. 4A ) and prefrontal cortex (t = 3.484, P = 0.0102) ( Fig. 4B ) compared to the levels in the WT-NS group. These results prompted us to question whether miR-32-5p is involved in the pathogenesis of LPS-induced depression.
MiR-32-5p knockout had potential anti-depression-like behavioral effects
The open field test was performed to determine animals' spontaneous locomotor activity and anxiety-like behaviors. Two-way ANOVA indicated there was no main effect of miR-32-5p knockout (F (1, 114) = 0.6194, P = 0.4329), LPS (F (1, 114) = 3.597, P = 0.0604) or the miR-32-5p knockout × LPS interaction (F (1, 114) = 1.640, P = 0.2030) on the locomotor activity among the groups (Fig. 5B) . The time spent in the center was not altered by miR-32-5p knockout (F (1, 85) = 0.4782, P = 0.4911) or LPS (F (1, 85) = 1.266, P = 0.2636), and there was no interaction effect (F (1, 85) = 0.003909, P = 0.9503) among the groups (Fig. 5C ), which suggests that miR-32-5p knockout or LPS did not affect animals' spontaneous locomotor activity and anxiety-like behavior.
We subsequently examined depression-like behavior using the forced swimming test and sucrose preference test. It was found that miR-32-5p knockout (F (1, 45) = 22.43, P < 0.0001), LPS (F (1, 45) = 16.88, P = 0.0002) and the miR-32-5p knockout × LPS interaction (F (1, 45) = 9.097, P = 0.0042) could affect the immobility time in the forced swim test. Bonferroni posttests showed that LPS led to a substantially increased immobility time compared with that observed in the NS group (t = 4.543, P <0.001),
and miR-32-5p knockout resulted in an immobility time similar to that of the NS animals (t = 5.605, P >0.05) (Fig. 5D ). Moreover, two-way ANOVA indicated there were significant effects of LPS (F (1, 100) = 14.77, P = 0.0002) and the miR-32-5p knockout × LPS interaction (F (1, 100) = 6.479, P = 0.0124) but no main effect of miR-32-5p knockout (F (1, 100) = 0.02816, P = 0.8671) on the sucrose preference in the sucrose preference test. Bonferroni posttests showed that the LPS-treated animals exhibited less preference for sucrose than the NS animals (t = 6.034, P <0.001) in the WT mice, and the miR-32-5p knockout mice exhibited no significant difference for sucrose preference between the LPS and NS treatments (t = 1.825, P >0.05) (Fig. 5E ).
Together, these results suggested that miR-32-5p knockout could ameliorate depressive-like behavior induced by LPS treatment in mice.
MiR-32-5p knockout did not affect LPS-induced microglial activation
To explore the molecular mechanisms associated with the phenotypes of miR-32-5p knockout that had anti-depression-like behavioral effects, we examined the alterations in the mRNA levels of microglial markers, such as IBA-1, CD68, CD11B and MHCII. In the hippocampus, it was found that LPS showed a main effect on microglial markers (IBA-1:F (1, 19) = 34.02, P < 0.001; CD68: F (1, 20) = 69.56, P < 0.001; CD11B: F (1, 20) = 105.2, P < 0.001; and MHCII: F (1, 17) = 11.54, P = 0.0034), but no significant effect of miR-32-5p knockout (IBA-1: F (1, 19) = 1.329e-005, P = 0.9971; CD68: F (1, 20) = 0.7327, P = 0.4021; CD11B: F (1, 20) = 0.1109, P = 0.7426;
and MHCII: F (1, 17) = 0.01302, P = 0.9105) or the miR-32-5p knockout × LPS interaction (IBA-1: F (1, 19) = 0.005171, P = 0.9434; CD68: F (1, 20) = 3.710, P = 0.0684;
CD11B: F (1, 20) = 0.5860, P = 0.4529; and MHCII: F (1, 17) = 0.07515, P = 0.7873) was found. The Bonferroni posttests analysis showed that LPS remarkably increased the mRNA levels of IBA-1 (t = 4.358, P < 0.01), CD68 (t = 7.311, P < 0.0001) and
CD11B (t = 7.850, P < 0.0001), which were not affected by miR-32-5p knockout (t = 0.05786, P > 0.05 for IBA-1; t = 2.056, P > 0.05 for CD68; t = 0.3196, P > 0.05 for CD11B) (Fig. 6A) .
Similarly, in the prefrontal cortex, the two-way ANOVA of the IBA-1 data indicated main effects of miR-32-5p knockout (F (1, 18) = 8.125, P = 0.0106) and LPS (F (1, 18) = 36.22, P < 0.0001), but no significant effect of the miR-32-5p knockout × LPS interaction (F (1, 18) = 0.2437, P = 0.6275). No change in the CD68 mRNA levels following miR-32-5p knockout (F (1, 18) = 0.3066, P = 0.5866), LPS (F (1, 18) = 3.306, P = 0.0857), or the interaction (F (1, 18) = 0.9029, P = 0.3546) was observed. Two-way ANOVA indicated a main effect of LPS (CD11B: F (1, 18) = 6.072, P = 0.0240; and MHCII: F (1, 17) = 24.44, P = 0.0001), but no significant effect of miR-32-5p knockout (CD11B:F (1, 18) = 2.633, P = 0.1221; and MHCII: F (1, 17) = 0.04724, P = 0.8305) or the miR-32-5p knockout × LPS interaction (CD11B: F (1, 18) = 0.2433, P = 0.6278; and MHCII:F (1, 17) = 0.0001546, P = 0.9902) on the CD11B or MHCII mRNA expression level was found. The Bonferroni posttests analysis showed that LPS remarkably increased the mRNA levels of IBA-1 (t = 3.706, P < 0.01) and MHCII (t = 3.290, P < 0.05), which were not affected by miR-32-5p knockout in the prefrontal cortex (t = 2.508, P > 0.05 for IBA-1; t = 0.1558, P > 0.05 for MHCII) (Fig. 6B ).
MiR-32-5p knockout did not affect LPS-induced microglia inflammation
We also examined alterations in the mRNA levels of inflammatory factors such as IL-1β, IL-1α, TNF-α, INOS, CCL2 and CXCL10. In the hippocampus, two-way ANOVA indicated there were significant effects of miR-32-5p knockout (IL-1β: F (1, 17) = 11.17, P < 0.0039; INOS: F (1, 18) = 5.374, P = 0.0324; and CXCL10: F (1, 18) miR-32-5p knockout among these inflammatory factors (Fig. 7A ).
In the prefrontal cortex, two-way ANOVA indicated there were significant effects of LPS (IL-1β: F (1, 18) = 8.079, P = 0.0108; IL-1α: F (1, 16) = 14.70, P = 0.0015;
TNF-α:F (1, 16) = 8.811, P = 0.0091; and CXCL10: F (1, 17) = 17.77, P = 0.0006), but no significant effect of miR-32-5p knockout (IL-1β: F (1, 18) = 0.03524, P = 0.8532 IL-1α:
F (1, 16) = 1.181, P = 0.2932; TNF-α: F (1, 16) = 3.703, P = 0.0723; and CXCL10: F (1, 17) = 0.5696, P = 0.4607) or the miR-32-5p knockout × LPS interaction (IL-1β: F (1, 18) = 2.363, P = 0.1416 IL-1α: F (1, 16) = 1.564, P = 0.2291; TNF-α: F (1, 16) = 2.773, P = 0.1153; and CXCL10: F (1, 17) = 0.2304, P = 0.6373) on the IL-1β, IL-1α, TNF-α and CXCL10 mRNA expressions. Two-way ANOVA indicated significant effects of miR-32-5p knockout (F (1, 18) = 5.816, P = 0.0268) and LPS (F (1, 18) = 41.12, P < 0.0001), but not of the miR-32-5p knockout × LPS interaction (F (1, 18) INOS (t = 6.016, P < 0.0001) and CXCL10 (t = 3.219, P < 0.05), but only the mRNA levels of INOS (t = 2.907, P < 0.05) were inhibited by miR-32-5p knockout among these inflammatory factors (Fig. 7B ). Altogether, these findings suggested that the inhibitory effect of miR-32-5p knockout on LPS-induced depression-like behaviors might not be due to its suppression of the release of inflammatory factors by microglia.
MiR-32-5p knockout inhibited LPS-induced astrocyte activation
To determine whether astrocytes were involved in the antidepressant-like effects of miR-32-5p knockout, we examined alterations in the expression of the astrocyte marker GFAP in the hippocampus and prefrontal cortex. Representative images of GFAP-positive cells are shown in Fig. 8A ; two-way ANOVA indicated significant effects of miR-32-5p knockout (CA1:F (1, 20) = 35.50, P < 0.0001; CA2: F (1, 18) = 54.74, P < 0.0001) and LPS (CA1: F (1, 20) = 11.19, P = 0.0032; CA2: F (1, 18) = 21.21, P = 0.0002), but not of the miR-32-5p knockout × LPS interaction (CA1:F (1, 20) F (1, 20) = 23.34, P = 0.0001; and DG: F (1, 20) = 22.37, P = 0.0001) and the miR-32-5p knockout × LPS interaction (CA3: F (1, 20) = 9.899, P = 0.0051; and DG: F (1, 20) = 12.17, P = 0.0023), but not of LPS (CA3: F (1, 20) = 3.007, P = 0.0983; and DG: F (1, 20) = 1.333, P = 0.2618). The Bonferroni posttests analysis showed that compared with the control, LPS remarkably increased the number of GFAP-positive cells in the CA1 (t = 3.813, P < 0.01), CA2 (t = 4.373, P < 0.01), CA3 (t = 3.451, P < 0.05) and DG (t = 3.283, P < 0.05), which was inhibited by miR-32-5p knockout (t = 5.660, P < 0.0001 for CA1; t = 6.984, P < 0.0001 for CA2; t = 5.641, P < 0.0001 for CA3; t = 0.5811, P < 0.0001 for DG) (Fig. 8B) .
We then examined alterations in the mRNA levels of GFAP in the hippocampus and prefrontal cortex. Two-way ANOVA indicated there were significant effects of miR-32-5p knockout (F (1, 19) = 15.49, P = 0.0009), LPS (F (1, 19) = 15.02, P = 0.0010) and the miR-32-5p knockout × LPS interaction (F (1, 19) = 4.554, P = 0.0461) on the expression of GFAP mRNA in the hippocampus (Fig. 8C) . The two-way ANOVA of the GFAP data indicated a main effect of miR-32-5p knockout (F (1, 18) = 16.28, P = 0.0008), but no significant effect of LPS (F (1, 18) = 0.1704, P = 0.6846) or the miR-32-5p knockout × LPS interaction (F (1, 18) = 1.734, P = 0.2044) in the prefrontal cortex (Fig. 8D) . The Bonferroni posttests analysis showed that compared with the control, LPS increased the levels of GFAP mRNA in the hippocampus (t = 4.435, P < 0.01), which was inhibited by miR-32-5p knockout (t = 4.649, P < 0.01) (Fig. 8C) .
miR-32-5p knockout decreased the mRNA levels of GFAP in the prefrontal cortex compared with the WT mice (t = 4.013, P < 0.01) (Fig. 8D ).
We also examined alterations in the protein levels of GFAP in the hippocampus and prefrontal cortex ( Fig. 8E & F) . Two-way ANOVA indicated significant effects of miR-32-5p knockout (Hip: F (1, 12) = 36.22, P < 0.0001; and PFC: F (1, 12) = 11.61, P = 0.0052 ) and the miR-32-5p knockout × LPS interaction (Hip: F (1, 12) = 9.003, P = 0.0111; and PFC: F (1, 12) = 12.74, P = 0.0039), but not for LPS (Hip: F (1, 12) = 1.368, P = 0.2649; and PFC: F (1, 12) = 0.3239, P = 0.5798) on the expression of GFAP in the hippocampus (Fig. 8G ) and prefrontal cortex (Fig. 8H) . The Bonferroni posttests analysis showed that miR-32-5p knockout decreased the expression of GFAP compared to that in the WT mice in both the hippocampus (t = 6.377, P < 0.001) and
prefrontal cortex (t = 4.933, P < 0.01).
MiR-32-5p knockout decreased LPS-induced expression of glutamate receptors
Astrocytes are crucial for glutamate uptake and metabolism in the central nervous system, and we examined alterations in the mRNA expression levels of glutamate receptors and transporters in both the hippocampus and prefrontal cortex. In the hippocampus, two-way ANOVA indicated there was a significant effect of miR-32-5p knockout (GluR1: F (1, 20) = 35.23, P < 0.0001; GluR2: F (1, 20) = 11.99, P = 0.0025; NMDAR1: F (1, 19) = 7.775, P = 0.0117; NMDAR2A: F (1, 19) = 13.26, P = 0.0017; and NMDAR2B: F (1, 20) = 14.46, P = 0.0011), but no significant effect of LPS (GluR1: F (1, 20) = 0.3242, P = 0.5754; GluR2: F (1, 20) = 1.112, P = 0.3041; NMDAR1:
F (1, 19) = 0.2295, P = 0.6374; NMDAR2A: F (1, 19) = 0.7102, P = 0.4099; and NMDAR2B: F (1, 20) = 0.02749, P = 0.87) or the miR-32-5p knockout × LPS interaction (GluR1: F (1, 20) = 0.01139, P = 0.9161; GluR2: F (1, 20) = 3.125, P = 0.0924; NMDAR1: F (1, 19) = 3.908, P = 0.0628; NMDAR2A: F (1, 19) = 1.721, P = 0.2052 ; and NMDAR2B: F (1, 20) = 0.04560, P = 0.8331) on the GluR1, GluR2, NMDAR1, NMDAR2A and NMDAR2B mRNA levels. The two-way ANOVA of the VGLUT2 data indicated a main effect of LPS (F (1, 19) = 9.654, P = 0.0058), but no significant effect of miR-32-5p knockout (F (1, 19) = 1.540, P = 0.2298) or the interaction (F (1, 19) = 1.845, P = 0.1903), and no effect of miR-32-5p knockout (F (1, 19) = 1.596, P = 0.2217), LPS (F (1, 19) = 0.03655, P = 0.8504) or the interaction (F (1, 19) = 0.1929, P = 0.6655) was observed on the EAAT1 mRNA level. The Bonferroni posttests analysis showed that miR-32-5p knockout decreased the mRNA levels of GluR1 (t = 4.307, P < 0.01), GluR2 (t = 3.865, P < 0.01), NMDAR1 (t = 3.607, P < 0.05), NMDAR2A (t = 3.794, P < 0.01) and NMDAR2B (t = 2.968, P < 0.05) in the hippocampus compared to the WT mice (Fig. 9A) . Similarly, in the prefrontal cortex, two-way ANOVA indicated there was a significant effect of miR-32-5p knockout (GluR1: F (1, 17) = 15.6, P = 0.0010; NMDAR2B: F (1, 18) = 16.13, P = 0.0008; and VGLUT2: F (1, 18) = 19.39, P = 0.0003), but no significant effect of LPS (GluR1: F (1, 17) = 2.399, P = 0.1398; NMDAR2B: F (1, 18) = 0.3915, P = 0.5393; and VGLUT2: F (1, 18) = 0.001510, P = 0.9694) or the miR-32-5p knockout × LPS interaction (GluR1: F (1, 17) = 1.466, P = 0.2426; NMDAR2B: F (1, 18) = 2.406, P = 0.1383; and VGLUT2: F (1, 18) = 1.600, P = 0.2220), on the GluR1, NMDAR2B and VGLUT2 mRNA levels. Moreover, there were no main effects of miR-32-5p knockout (GluR2: F (1, 16) = 4.264, P = 0.0555;
NMDAR2A: F (1, 17) = 0.9492, P = 0.3436), LPS (GluR2: F (1, 16) = 0.1067, P = 0.7482;
NMDAR2A: F (1, 17) = 0.0001377, P = 0.9908) or the miR-32-5p knockout × LPS interaction (GluR2: F (1, 16) = 0.5346, P = 0.4753; and NMDAR2A: F (1, 17) = 1.719, P = 0.2072) on the GluR2 or NMDAR2 mRNA expression. Two-way ANOVA indicated significant effects of miR-32-5p knockout (F (1, 17) = 20.31, P = 0.0003) and
the miR-32-5p knockout × LPS interaction (F (1, 17) = 15.89, P = 0.001), but not for LPS (F (1, 17) = 0.003853, P = 0.9512), on the expression of NMDAR1 mRNA.
Moreover, there were significant effects of miR-32-5p knockout (F (1, 18) = 17.30, P = 0.0006), LPS (F (1, 18) = 18.84, P = 0.0004) and the miR-32-5p knockout × LPS interaction (F (1, 18) = 21.74, P = 0.0002) on the EAAT1 mRNA expression level. The
Bonferroni posttests analysis showed that miR-32-5p knockout decreased the levels of GluR1 (t = 4.079, P < 0.01), NMDAR1 (t = 6.206, P < 0.0001), NMDAR2B (t = 4.175, P < 0.01), VGLUT2 (t = 4.251, P < 0.01) and EAAT1 (t = 6.617, P < 0.0001) compared to those in the WT mice (Fig. 9B ).
We also detected the protein expression levels of glutamate receptors and transporters. In the hippocampus (Fig. 9C) , two-way ANOVA indicated main effects of miR-32-5p knockout (GluR1: F (1, 28) = 23.23, P < 0.0001; and NMDAR2A: F (1, 28) = 86.09, P < 0.0001) and LPS (GluR1: F (1, 28) = 4.551, P = 0.0418; and NMDAR2A:
F (1, 28) = 4.838, P = 0.0363), but no significant effect of the miR-32-5p knockout × LPS interaction (GluR1: F (1, 28) = 2.896, P = 0.0999; and NMDAR2A: F (1, 28) = 2.852, P = 0.1024), on the GluR1 and NMDAR2A protein expressions. Two-way ANOVA indicated a significant effect of miR-32-5p knockout (NMDAR2B: F (1, 28) = 57.24, P < 0.0001; and VGLUT2: F (1, 11) = 8.193, P = 0.0155), but no significant effect of LPS (NMDAR2B: F (1, 28) = 0.4886, P = 0.4903; and VGLUT2: F (1, 11) = 1.331, P = 0.2730) or the miR-32-5p knockout × LPS interaction (NMDAR2B: F (1, 28) = 1.100, P = 0.3031; and VGLUT2: F (1, 11) = 1.142, P = 0.3082), on the NMDAR2B and VGLUT2 protein expressions. However, there were no main effects of miR-32-5p knockout (GluR2: F (1, 28) = 1.826, P = 0.1874; NMDAR1: F (1, 26) = 0.02197, P = 0.8833; and EAAT1: F (1, 12) = 0.02759, P = 0.8708), LPS (GluR2: F (1, 28) = 0.3863, P = 0.5393; NMDAR1: F (1, 26) = 1.869, P = 0.1833; and EAAT1: F (1, 12) = 0.3609, P = 0.5592) or the miR-32-5p knockout × LPS interaction (GluR2: F (1, 28) = 0.6227, P = 0.4367; NMDAR1: F (1, 26) = 0.3369, P = 0.5666; and EAAT1: F (1, 12) = 1.144, P = 0.3059) on the GluR2, NMDAR1 or EAAT1 protein expression. The Bonferroni posttests analysis showed that miR-32-5p knockout decreased the levels of GluR1 (t = 4.611, P < 0.001), NMDAR2A (t = 7.755, P < 0.0001) and NMDAR2B (t = 6.091, P < 0.0001) compared to those in the WT mice (Fig. 9E ). In the prefrontal cortex ( Fig. 9D) , two-way ANOVA indicated significant effects of miR-32-5p knockout (GluR1: F (1, 26) = 6.976, P = 0.0138; NMDAR2A: F (1, 28) = 7.892, P = 0.0090; and VGLUT2: F (1, 11) = 6.847, P = 0.0240) and the miR-32-5p knockout × LPS interaction (GluR1: F (1, 26) = 9.469, P = 0.0049; NMDAR2A: F (1, 28) = 26.61, P <0.0001; and VGLUT2: F (1, 11) = 13.33, P = 0.0038), but no significant effect of LPS (GluR1: F (1, 26) = 0.6465, P = 0.4287; NMDAR2A: F (1, 28) = 0.9765, P = 0.3315; and VGLUT2: F (1, 11) = 0.2143, P = 0.6524), on the GluR1, NMDAR2A and VGLUT2 protein expressions. Moreover, the GluR2 data indicated a significant effect of the miR-32-5p knockout× LPS interaction (F (1, 28) = 8.807, P = 0.0061), but no significant effect of miR-32-5p knockout (F (1, 28) = 0.8944, P = 0.3524) or LPS (F (1, 28) = 1.412, P = 0.2447). The two-way ANOVA of the NMDAR1 data indicated main effects of LPS (F (1, 12) = 6.565, P = 0.00249) and the miR-32-5p knockout × LPS interaction (F (1, 12) = 16.77, P = 0.0015) but no significant effect of miR-32-5p knockout (F (1, 26) = 0.5429, P = 0.4754). Two-way ANOVA indicated there were significant effects of miR-32-5p knockout (F (1, 11) = 29.40, P = 0.0002), LPS (F (1, 11) = 7.603, P = 0.0186) and the miR-32-5p knockout × LPS interaction (F (1, 11) = 9.543, P = 0.0103) on the NMDAR2B protein expression. The two-way ANOVA of the EAAT1 data indicated no effect of miR-32-5p knockout (F (1, 11) = 1.005, P = 0.3376), LPS (F (1, 11) = 0.03899, P = 0.8471) or the miR-32-5p knockout × LPS interaction (F (1, 11) = 0.9946, P = 0.3401). The Bonferroni posttests analysis showed that LPS remarkably upregulated the levels of GluR1 (t = 2.856, P < 0.05), GluR2 (t = 2.939, P < 0.05), NMDAR1 (t = 4.707, P < 0.01), NMDAR2A (t = 4.346, P < 0.001) and NMDAR2B
(t = 4.303, P < 0.01) compared with the control, which were inhibited by miR-32-5p knockout (t = 4.209, P < 0.01 for GluR1; t = 5.634, P < 0.0001 for NMDAR2A; t = 5.800, P < 0.001 for NMDAR2B and t = 4.270, P < 0.01 for VGLUT2) (Fig. 9F) .
Discussion
In the present study, we found miR-32-5p was widely expressed in the prefrontal cortex and hippocampus in WT mice, and we then investigated the phenotypes of miR-32-5p knockout mice and determined the effect of miR-32-5p on depression-like behaviors induced by LPS in mice. It was found that miR-32-5p knockout had no effect on neuronal toxicity or general behavior in mice. To understand the role of miR-32-5p in the progression of depression, we developed a depression-like behavior mouse model with LPS administration, and we verified that the knockout of miR-32-5p ameliorated LPS-induced depression-like behaviors. Further mechanistic investigations indicated that miR-32-5p knockout repressed the activation of astrocytes and eliminated glutamatergic dysregulation in the prefrontal cortex and hippocampus.
miRNAs are small, noncoding RNAs that are involved in posttranscriptional regulation of gene expression and bind to complementary sequences of target mRNAs to induce translational repression or mRNA degradation (Hobert 2008) . There is an
increasing body of evidence that shows miRNAs regulate neuronal and synaptic plasticity (Rajasethupathy et al. 2009; O'Carroll et al. 2013) . We previously identified microRNA-32-5p as an essential modulator for vascular calcification ,
which was shown to be closely associated with depression and central nervous system diseases (Hamer et al. 2010; Zhang et al. 2018; Lin et al. 2018b) . Moreover, in our present study, we found that miR-32-5p was widely expressed in the prefrontal cortex and hippocampus in WT mice. Therefore, we investigated whether miR-32-5p had a regulatory role in central nervous system-associated diseases. We found that the loss of miR-32-5p did not alter anxiety, depression or social behavior in mice under basal conditions. In addition, we did not observe neuronal loss after miR-32-5p knockout based on the results of Nissl staining and NeuN expression. Moreover, microglial markers were not significantly different in WT mice compared with miR-32-5p knockout mice, which suggests that miR-32-5p knockout has no effect on glial proliferation. These results indicate that miR-32-5p deficiency has no effect on normal behaviors or brain development.
microRNAs (miRNAs) have been suggested to play an essential role in the pathophysiology of depressive disorders (Geaghan et al. 2015a) . miRNAs may participate in the pathophysiology of depression through synaptic plasticity (Gao et al. 2010 ), neurogenesis (Choi et al. 2008 ) and gene expression regulation of key signaling transduction pathways (Xu et al. 2010 ). In addition, both preclinical and clinical studies showed that miRNAs might contribute to antidepressant drug actions (Issler et al. 2015; Geaghan et al. 2015b; Kocerha et al. 2015) . Peripheral administration of lipopolysaccharide (LPS) was confirmed to lead to depression-like behavior in rodents, accompanied by activated brain glia and remarkable changes in glutamate systems (Miller et al. 2016; Wohleb et al. 2016) . In this study, we utilized an LPS-induced depressive mouse model to assess the potential role of miR-32-5p in the pathophysiology of depression. Consistent with previous studies, we demonstrated that LPS could lead to immune activation and cause pro-inflammatory cytokine-dependent depressive behaviors in mice. The expression of miR-32-5p was also elevated by LPS in the hippocampus and prefrontal cortex. The results from the sucrose preference test and forced swimming test demonstrated that miR-32-5p knockout in mice eliminated LPS-induced depression-like behaviors, which indicated that miR-32-5p might be involved in regulating depression psychopathology.
Astrocytes are crucial for glutamate uptake and metabolism in the central nervous system (Dallerac et al. 2018) . In response to CNS insult, astrocytes developed a hypertrophic or reactive phenotype termed astrogliosis (Levine et al. 1999) , which is characterized by an upregulation of GFAP (Ridet et al. 1996) . Acute treatment with LPS also enhanced glutamate release in the rodent hippocampus (Guo et al. 2016) . (Liu et al. 2018) . In this work, we found enhanced expression of microglial markers, astrocyte markers and pro-inflammatory cytokines in the hippocampus and prefrontal cortex of LPS-treated mice. Moreover, the expression of glutamate receptors, such as GluR1 and NMDAR2A, was also significantly enhanced in the hippocampus and prefrontal cortex of LPS-treated mice. Consistently, LPS-induced activation of astrocytes and dysfunction of glutamatergic signaling were eliminated in miR-32-5p knockout mice. Therefore, it could be inferred that miR-32-5p is implicated in LPS-induced aberrant activation of astrocytes, which could partly explain the mechanism by which miR-32-5p contributed to LPS-induced depression-like behaviors. The corresponding targeted genes and signals responsible for the role of miR-32-5p in the psychopathological progression of depression still need to be further verified and validated. Our previous work verified that miR-32-5p
was an essential modulator of vascular calcification, and the findings of a contribution of miR-32-5p to LPS-induced depression suggest that miR-32-5p might function as a key interlinkage between vascular calcification and depression progression.
In summary, for the first time, we developed an miR-32-5p knockout mouse model and confirmed the important function of miR-32-5p in enhancing the psychopathological progression of depression in mice. The present work provided evidence that miR-32-5p might serve as a novel target for biomarker and drug development for the treatment of inflammation-induced depression.
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